Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
about
Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.Clinical application of DNA ploidy to cervical cancer screening: A review.A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening resultsAge-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies.Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type.A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results.Single and multiple high-risk and low-risk Human Papillomavirus association with cervical lesions of 11,224 women in Jakarta.Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.A joint model of persistent human papillomavirus infection and cervical cancer risk: Implications for cervical cancer screening.p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive WomenA Suggested Approach to Simplify and Improve Cervical Screening in the United States.Triage of HPV positive women in cervical cancer screening.Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results.Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 yearsFollow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or lessFive-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.Diagnostic Approach to Patients with Atypical Squamous Cells of Undetermined Significance Cytologic Findings on CervixLong-term cumulative incidence of cervical intraepithelial neoplasia grade 3 or worse after abnormal cytology: impact of HIV infection.A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology.Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.A cohort study of cervical screening using partial HPV typing and cytology triage.Prophylactic HPV vaccination: past, present, and future.Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.Management algorithms for cervical cancer screening and precancer treatment for resource-limited settings.Risk of HSIL (CIN 2-3) on colposcopic biopsy is minimal in postmenopausal women with LSIL on cytology and a negative HRHPV test.Risk assessment to guide cervical screening strategies in a large Chinese population.Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.
P2860
Q30354591-377D3498-54CC-470B-9D8B-7626D8D22B4DQ30409120-0C22A35D-98D2-4D0E-A50E-159C769C0045Q33951517-7D2EB148-B189-48C0-8F77-3197C2F9EAA7Q34657755-6CB32569-43D2-4696-AA94-2E3784F409F7Q34916671-8C5272F1-5ABA-43D4-A61F-ED1DE2F95196Q35039759-18A3C017-EDBC-489B-AFF9-E522706818ACQ35282164-B1385B65-095A-4702-811D-BE7772553389Q35665790-02279B32-4C69-4A19-9680-555EFFD047D0Q36016617-3F502049-26F8-4CD1-85E5-37F20626205FQ36165724-F5F3660D-97ED-4C2D-8A9D-E752766CC61BQ36187634-1850E4FD-95A9-4438-BE9F-FAE07372DA56Q36254941-62E10762-0E54-4FA1-8AA2-C9D23E62725DQ36361863-66DE7D73-B88A-4EC2-B8AA-602A58F0C614Q36407125-FEABFECF-2EBC-4CA3-886D-224A7B657CD9Q36679896-606758AD-8F38-4249-A31F-0D54762CBD71Q36739942-F58C9A1D-1AD3-4345-A380-5E873C8CD686Q36740029-671719A7-E821-4313-A3EA-246B859FA87EQ36740033-B637ECE0-7199-4024-9830-A96484BBDF51Q36740038-3454D75A-E0F3-4B03-B731-ABFCA1344CECQ36740199-7D88DF17-A07E-49C7-B893-B6515DB59C74Q36740209-1FB02B72-500B-4CDF-AA07-6371814DE621Q36799898-03683C48-5511-4986-AEF1-D2A0B4A30A64Q36984154-AD5E60BF-AEB3-4382-A30E-970780950B2CQ37225246-6F1611DA-70CF-4E21-BBC0-7069ECEAE72AQ37279920-B7A5C44C-1CC2-4620-B517-F0330AB78180Q37626416-292600BE-C6B2-4E45-9A0C-A76DCA8DBFDAQ38248178-EB0FC91E-EBFF-4A0A-9524-1333832F9109Q38255277-8FB0D711-182B-445C-BFA8-C0FE05AA7061Q38378838-DDFD51F8-1BB0-4D1B-B1B9-2E2883E55F0CQ38597567-3E5C4EAD-D0E4-45D7-AC71-E635E88225FAQ38703134-688518BE-9A2C-4290-A39C-DAD00791099DQ39204728-B3EBEFEB-BF63-4865-B903-4247C7AFEC3EQ39362235-B3D8232C-D7C4-4801-807B-24D0B3ACFC56Q40129828-22B46189-F9D4-4BBB-A66D-97081AE7E032Q40620973-95703BD1-0670-43BD-A97F-3979288971F8Q40821522-EC554434-D5E5-4E03-B01D-7D7A28432344Q42369427-F0548D8C-C146-4C61-A56F-482342BFA04CQ42709627-31D3F462-F599-44DA-8692-853A886AC8E3Q43924111-C794E8AF-18B8-472B-92D1-9E7A45F17FE5Q46075408-3E91DC7A-A8E3-4603-8FCF-B88AF02D73EB
P2860
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Benchmarking CIN 3+ risk as th ...... ing and management guidelines.
@ast
Benchmarking CIN 3+ risk as th ...... ing and management guidelines.
@en
type
label
Benchmarking CIN 3+ risk as th ...... ing and management guidelines.
@ast
Benchmarking CIN 3+ risk as th ...... ing and management guidelines.
@en
prefLabel
Benchmarking CIN 3+ risk as th ...... ing and management guidelines.
@ast
Benchmarking CIN 3+ risk as th ...... ing and management guidelines.
@en
P2093
P2860
P1476
Benchmarking CIN 3+ risk as th ...... ing and management guidelines.
@en
P2093
Barbara Fetterman
Hormuzd A Katki
Julia C Gage
Li C Cheung
Nancy E Poitras
Philip E Castle
Thomas Lorey
Tina Raine-Bennett
Walter K Kinney
P2860
P304
P356
10.1097/LGT.0B013E318285423C
P433
P577
2013-04-01T00:00:00Z